Perioperative treatment and radical cystectomy for bladder cancer - A population based trend analysis of 10,338 patients in the Netherlands

European Journal of Cancer

Volumn 54, Issue , 2016, Pages 18-26

  Hermans, Tom J N ^a   Fransen Van De Putte, Elisabeth E ^a   Horenblas, Simon ^a   Lemmens, Valery ^b,c   Aben, Katja ^b,d   Van Der Heijden, Michiel S ^a   Beerepoot, Laurens V ^e   Verhoeven, Rob H ^b   Van Rhijn, Bas W G ^a  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^b Netherlands Comprehensive Cancer Organisation ^*  (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e CPRLab   (Netherlands)

Author keywords

Adjuvant; Bladder; Cancer; Chemotherapy; Cystectomy; Neoadjuvant; Radiotherapy

Indexed keywords

ADULT; AGED; BLADDER CANCER; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CHILD; CYSTECTOMY; FEMALE; HUMAN; INDUCTION CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NETHERLANDS; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; TEACHING HOSPITAL; ADJUVANT CHEMOTHERAPY; ADJUVANT RADIOTHERAPY; ADOLESCENT; AGE; CANCER GRADING; CLINICAL PRACTICE; INFANT; MULTIVARIATE ANALYSIS; NEOADJUVANT THERAPY; NEWBORN; PATHOLOGY; PRESCHOOL CHILD; REGISTER; STATISTICAL MODEL; TIME FACTOR; TREATMENT OUTCOME; TRENDS; URINARY BLADDER NEOPLASMS; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; CHEMOTHERAPY, ADJUVANT; CHILD; CHILD, PRESCHOOL; CYSTECTOMY; FEMALE; HOSPITALS, TEACHING; HUMANS; INFANT; INFANT, NEWBORN; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOADJUVANT THERAPY; NEOPLASM GRADING; NEOPLASM STAGING; NETHERLANDS; PRACTICE PATTERNS, PHYSICIANS'; RADIOTHERAPY, ADJUVANT; REGISTRIES; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS; YOUNG ADULT;

EID: 84950262423     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2015.11.006     Document Type: Article

References (33)

1. P. Zehnder, U.E. Studer, E.C. Skinner, G.N. Thalmann, G. Miranda, B. Roth, and et al. Unaltered oncological outcomes of radical cystectomy with extended lymphadenectomy over three decades BJU Int 112 2013 51 58
2. M. Huncharek, J. Muscat, and J.F. Geschwind Planned preoperative radiation therapy in muscle invasive bladder cancer; results of a meta-analysis Anticancer Res 18 1998 1931 1934
3. J.J. Leow, W. Martin-Doyle, P.S. Rajagopal, C.G. Patel, E.M. Anderson, A.T. Rothman, and et al. Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials Eur Urol 66 2014 42 54
4. Advanced Bladder Cancer Meta-analysis C Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration Eur Urol 48 2005 202 205
5. M.S. Zaghloul, H.K. Awwad, H.H. Akoush, S. Omar, O. Soliman, and I. el Attar Postoperative radiotherapy of carcinoma in bilharzial bladder: improved disease free survival through improving local control Int J Radiat Oncol Biol Phys 23 1992 511 517
6. H. Zargar, P.N. Espiritu, A.S. Fairey, L.S. Mertens, C.P. Dinney, M.C. Mir, and et al. Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer Eur Urol 67 2015 241 249
7. H.B. Grossman, R.B. Natale, C.M. Tangen, V.O. Speights, N.J. Vogelzang, D.L. Trump, and et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer N Engl J Med 349 2003 859 866
8. G. Griffiths, R. Hall, R. Sylvester, D. Raghavan, M.K. Parmar, International Collaboration of T, Medical Research Council Advanced Bladder Cancer Working P, European Organisation for R, and et al. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial J Clin Oncol 29 2011 2171 2177
9. R. Rosenblatt, A. Sherif, E. Rintala, R. Wahlqvist, A. Ullén, S. Nilsson, and et al. Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer Eur Urol 61 2012 1229 1238
10. Z.D. Reardon, S.G. Patel, H.B. Zaid, C.J. Stimson, M.J. Resnick, K.A. Keegan, and et al. Trends in the use of perioperative chemotherapy for localized and locally advanced muscle-invasive bladder cancer: a sign of changing tides Eur Urol 67 2015 165 170
11. M. Burger, P. Mulders, and W. Witjes Use of neoadjuvant chemotherapy for muscle-invasive bladder cancer is low among major European centres: results of a feasibility questionnaire Eur Urol 61 2012 1070 1071
12. R.H. Thompson, S.A. Boorjian, S.P. Kim, J.C. Cheville, P. Thapa, R. Tarrel, and et al. Eligibility for neoadjuvant/adjuvant cisplatin-based chemotherapy among radical cystectomy patients BJU Int 113 2014 17 21
13. D. Canter, R. Viterbo, A. Kutikov, Y.N. Wong, E. Plimack, F. Zhu, and et al. Baseline renal function status limits patient eligibility to receive perioperative chemotherapy for invasive bladder cancer and is minimally affected by radical cystectomy Urology 77 2011 160 165
14. S.M. Donat, A. Shabsigh, C. Savage, A.M. Cronin, B.H. Bochner, G. Dalbagni, and et al. Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience Eur Urol 55 2009 177 185
15. M. Casparie, A.T. Tiebosch, G. Burger, H. Blauwgeers, A. van de Pol, J.H. van Krieken, and et al. Pathology databanking and biobanking in the Netherlands, a central role for PALGA, the nationwide histopathology and cytopathology data network and archive Cell Oncol 29 2007 19 24
16. A.P.C. Fritz, and A. Jack International classification of disease for oncology 3rd edn. 2000 World Health Organization Geneva
17. L.H. Sobin, G.M. Gospodarowicz, and C. Wittekind TNM atlas 7th edn. 2009 Wiley-Blackwell
18. J.A. Witjes, E. Compérat, N.C. Cowan, M. De Santis, G. Gakis, T. Lebret, and et al. EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines Eur Urol 65 2014 778 792
19. C. Rödel, G.G. Grabenbauer, R. Kühn, T. Papadopoulos, J. Dunst, M. Meyer, and et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results J Clin Oncol 20 2002 3061 3071
20. K.S. Oh, D.E. Soto, D.C. Smith, J.E. Montie, C.T. Lee, and H.M. Sandler Combined-modality therapy with gemcitabine and radiation therapy as a bladder preservation strategy: long-term results of a phase I trial Int J Radiat Oncol Biol Phys 74 2009 511 517
21. M.S. Zaghloul The need to revisit adjuvant and neoadjuvant radiotherapy in bladder cancer Expert Rev Anticancer Ther 10 2010 1527 1528
22. T. Granfors, R. Tomic, and B. Ljungberg Downstaging and survival benefits of neoadjuvant radiotherapy before cystectomy for patients with invasive bladder carcinoma Scand J Urol Nephrol 43 2009 293 299
23. C.N. Sternberg, I. Skoneczna, J.M. Kerst, P. Albers, S.D. Fossa, M. Agerbaek, and et al. Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial Lancet Oncol 16 2015 76 86
24. L.S. Mertens, R.P. Meijer, W. Meinhardt, H.G. van der Poel, A. Bex, J.M. Kerst, and et al. Occult lymph node metastases in patients with carcinoma invading bladder muscle: incidence after neoadjuvant chemotherapy and cystectomy vs after cystectomy alone BJU Int 114 2014 67 74
25. K. Zargar-Shoshtari, H. Zargar, Y. Lotan, and et al. A multi-institutional analysis of outcomes in patients with clinically node positive urothelial bladder cancer treated with induction chemotherapy and radical cystectomy J Urol 2015 Jul 21 pii: S0022-5347(15)04421-3. [Epub ahead of print]
26. C.A. Goossens-Laan, A.M. Leliveld, R.H. Verhoeven, P.J. Kil, G.H. de Bock, M.C. Hulshof, and et al. Effects of age and comorbidity on treatment and survival of patients with muscle-invasive bladder cancer Int J Cancer 135 4 2014 905 912
27. A. Bamias, E. Efstathiou, L.A. Moulopoulos, D. Gika, G. Hamilos, M.P. Zorzou, and et al. The outcome of elderly patients with advanced urothelial carcinoma after platinum-based combination chemotherapy Ann Oncol 16 2005 307 313
28. C.A. Goossens-Laan, O. Visser, M.W. Wouters, M.L. Jansen-Landheer, J.W. Coebergh, C.J. van de Velde, and et al. Variations in treatment policies and outcome for bladder cancer in the Netherlands Eur J Surg Oncol 36 Suppl. 2010 100 107
29. C.G. Moertel, T.R. Fleming, J.S. Macdonald, D.G. Haller, J.A. Laurie, C.M. Tangen, and et al. Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer J Clin Oncol 13 1995 2936 2943
30. C.B. van den Broek, E. Bastiaannet, J.W. Dekker, J.E. Portielje, A.J. de Craen, M.A. Elferink, and et al. Time trends in chemotherapy (administration and costs) and relative survival in stage III colon cancer patients - a large population-based study from 1990 to 2008 Acta Oncol 52 2013 941 949
31. C. Chakiba, F. Cornelis, E. Descat, M. Gross-Goupil, P. Sargos, G. Roubaud, and et al. Dynamic contrast enhanced MRI-derived parameters are potential biomarkers of therapeutic response in bladder carcinoma Eur J Radiol 84 2015 1023 1028
32. T. Powles, J.P. Eder, G.D. Fine, F.S. Braiteh, Y. Loriot, C. Cruz, and et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer Nature 515 2014 558 562
33. F.H. Groenendijk, J. de Jong, E.E. Fransen van de Putte, M. Michaut, A. Schlicker, D. Peters, and et al. ERBB2 mutations characterize a subgroup of muscle-invasive bladder cancers with excellent response to neoadjuvant chemotherapy Eur Urol 2015 Jan 27 pii: S0302-2838(15)00037-8. [Epub ahead of print]